1
|
Wolfsberg TG and White JM: ADAMs in
fertilization and development. Dev Biol. 180:389–401. 1996.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Seals DF and Courtneidge SA: The ADAMs
family of metallo-proteases: multidomain proteins with multiple
functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
3
|
Arribas J, Bech-Serra JJ and
Santiago-Josefat B: ADAMs, cell migration and cancer. Cancer
Metastasis Rev. 25:57–68. 2006. View Article : Google Scholar : PubMed/NCBI
|
4
|
Krätzschmar J, Lum L and Blobel CP:
Metargidin, a membrane-anchored metalloprotease-disintegrin protein
with an RGD integrin binding sequence. J Biol Chem. 271:4593–4596.
1996. View Article : Google Scholar : PubMed/NCBI
|
5
|
Zhang XP, Kamata T, Yokoyama K,
Puzon-McLaughlin W and Takada Y: Specific interaction of the
recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15)
with integrin alphavbeta3. J Biol Chem. 273:7345–7350. 1998.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Eto K, Puzon-McLaughlin W, Sheppard D,
Sehara-Fujisawa A, Zhang XP and Takada Y: RGD-independent binding
of integrin alpha9beta1 to the ADAM-12 and -15 disintegrin domains
mediates cell-cell interaction. J Biol Chem. 275:34922–34930. 2000.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Nath D, Slocombe PM, Stephens PE, et al:
Interaction of metargidin (ADAM-15) with alphavbeta3 and
alpha5beta1 integrins on different haemopoietic cells. J Cell Sci.
112:579–587. 1999.PubMed/NCBI
|
8
|
Herren B, Garton KJ, Coats S, Bowen-Pope
DF, Ross R and Raines EW: ADAM15 overexpression in NIH3T3 cells
enhances cell-cell interactions. Exp Cell Res. 271:152–160. 2001.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Moss ML and Bartsch JW: Therapeutic
benefits from targeting of ADAM family members. Biochemistry.
43:7227–7235. 2004. View Article : Google Scholar : PubMed/NCBI
|
10
|
Trochon-Joseph V, Martel-Renoir D, Mir LM,
et al: Evidence of antiangiogenic and antimetastatic activities of
the recombinant disintegrin domain of metargidin. Cancer Res.
64:2062–2069. 2004. View Article : Google Scholar : PubMed/NCBI
|
11
|
O’Reilly MS, Boehm T, Shing Y, et al:
Endostatin: an endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar
|
12
|
O’Reilly MS, Holmgren L, Shing Y, et al:
Angiostatin: a novel angiogenesis inhibitor that mediates the
suppression of metastases by a Lewis lung carcinoma. Cell.
79:315–328. 1994. View Article : Google Scholar
|
13
|
Herren B, Raines EW and Ross R: Expression
of a disintegrin-like protein in cultured human vascular cells and
in vivo. FASEB J. 11:173–180. 1997.PubMed/NCBI
|
14
|
Brooks PC, Montgomery AM, Rosenfeld M, et
al: Integrin alpha v beta 3 antagonists promote tumor regression by
inducing apoptosis of angiogenic blood vessels. Cell. 79:1157–1164.
1994. View Article : Google Scholar : PubMed/NCBI
|
15
|
Horiuchi K, Weskamp G, Lum L, et al:
Potential role for ADAM15 in pathological neovascularization in
mice. Mol Cell Biol. 23:5614–5624. 2003. View Article : Google Scholar : PubMed/NCBI
|
16
|
Wu J, Zhang L, Lei J, et al: Enhancement
of recombinant human ADAM15 disintegrin domain expression level by
releasing the rare codons and amino acids restriction. Appl Biochem
Biotechnol. 157:299–310. 2009. View Article : Google Scholar
|
17
|
Hou Y, Chu M, Du FF, et al: Recombinant
disintegrin domain of ADAM15 inhibits the proliferation and
migration of Bel-7402 cells. Biochem Biophys Res Commun.
435:640–645. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Halpern ME, Thisse C, Ho RK, et al:
Cell-autonomous shift from axial to paraxial mesodermal development
in zebrafish floating head mutants. Development. 121:4257–4264.
1995.PubMed/NCBI
|
19
|
Chang YM, Bai L, Liu S, Yang JC, Kung HJ
and Evans CP: Src family kinase oncogenic potential and pathways in
prostate cancer as revealed by AZD0530. Oncogene. 27:6365–6375.
2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Kuefer R, Day KC, Kleer CG, et al: ADAM15
disintegrin is associated with aggressive prostate and breast
cancer disease. Neoplasia. 8:319–329. 2006. View Article : Google Scholar : PubMed/NCBI
|
21
|
Bridges LC, Sheppard D and Bowditch RD:
ADAM disintegrin-like domain recognition by the lymphocyte
integrins alpha4beta1 and alpha4beta7. Biochem J. 387:101–108.
2005. View Article : Google Scholar :
|
22
|
Beck V, Herold H, Benge A, et al: ADAM15
decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer
cell adhesion and motility in an RGD-dependent fashion. Int J
Biochem Cell Biol. 37:590–603. 2005. View Article : Google Scholar
|
23
|
Jain RK, Duda DG, Clark JW and Loeffler
JS: Lessons from phase III clinical trials on anti-VEGF therapy for
cancer. Nat Clin Pract Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI
|
24
|
Ferrara N: VEGF-A: a critical regulator of
blood vessel growth. Eur Cytokine Netw. 20:158–163. 2009.
|
25
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Drake CJ, Cheresh DA and Little CD: An
antagonist of integrin alpha v beta 3 prevents maturation of blood
vessels during embryonic neovascularization. J Cell Sci.
108:2655–2661. 1995.PubMed/NCBI
|
27
|
Hammes HP, Brownlee M, Jonczyk A, Sutter A
and Preissner KT: Subcutaneous injection of a cyclic peptide
antagonist of vitro-nectin receptor-type integrins inhibits retinal
neovascularization. Nat Med. 2:529–533. 1996. View Article : Google Scholar : PubMed/NCBI
|
28
|
Kerr JS, Wexler RS, Mousa SA, et al: Novel
small molecule alpha v integrin antagonists: comparative
anti-cancer efficacy with known angiogenesis inhibitors. Anticancer
Res. 19:959–968. 1999.PubMed/NCBI
|
29
|
Patel SR, Jenkins J, Papadopolous N, et
al: Pilot study of vitaxin - an angiogenesis inhibitor-in patients
with advanced leiomyosarcomas. Cancer. 92:1347–1348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Cheng J, Gu YJ, Wang Y, Cheng SH and Wong
WT: Nanotherapeutics in angiogenesis: synthesis and in vivo
assessment of drug efficacy and biocompatibility in zebrafish
embryos. Int J Nanomedicine. 6:2007–2021. 2011. View Article : Google Scholar : PubMed/NCBI
|
31
|
Sofia Vala I, Martins LR, Imaizumi N, et
al: Low doses of ionizing radiation promote tumor growth and
metastasis by enhancing angiogenesis. PLoS One. 5:e112222010.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Serbedzija GN, Flynn E and Willett CE:
Zebrafish angiogenesis: a new model for drug screening.
Angiogenesis. 3:353–359. 1999. View Article : Google Scholar
|
33
|
Crociani O, Zanieri F, Pillozzi S, et al:
hERG1 channels modulate integrin signaling to trigger angiogenesis
and tumor progression in colorectal cancer. Sci Rep. 3:33082013.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Lucena SE, Romo K, Suntravat M and Sanchez
EE: Anti-angiogenic activities of two recombinant disintegrins
derived from the Mohave and Prairie rattlesnakes. Toxicon.
78:10–17. 2014. View Article : Google Scholar :
|